Robbins Geller Rudman & Dowd LLP said investors who purchased or acquired Alibaba Group Holding Limited publicly traded securities during the June 26, 2025, to June 24, 2026, class period have until October 5, 2026, to seek appointment as lead plaintiff in Wistisen v. Alibaba Group Holding Limited, No. 26-cv-06654 (S.D.N.Y.). The lawsuit names Alibaba and its Chief Executive Officer and alleges violations of the Securities Exchange Act of 1934. The complaint claims Alibaba failed to disclose alleged direct or indirect control by, or affiliation with, China’s Ministry of Industry and Information Technology, which the complaint says could make it a Chinese military company under the National Defense Authorization Act. It also alleges that Alibaba-linked operators engaged in ongoing adversarial distillation attacks against third-party AI models. The complaint cites an updated U.S. Department of Defense list released after market hours on June 8, 2026, that included Alibaba, after which Alibaba ADSs declined nearly 4%. It also cites a June 24 Bloomberg report about Anthropic’s allegations involving Alibaba’s Qwen AI lab; the complaint says ADSs fell 2.7% on June 24 and another 4.7% on June 25. An earlier investor notice described the case using a different docket-number format and reported dollar-denominated price changes, creating discrepancies that remain unresolved. Investors do not need to become lead plaintiff to share in any potential recovery.